Company intelligence / Profile preview
Ibex Biosciences
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Ibex Biosciences develops therapeutic antibodies, gene therapies, and regenerative medicine solutions using a proprietary approach focused on novel discovery rather than external licensing. The company has demonstrated preclinical efficacy in animal models across several challenging medical conditions and holds patents including one for targeting PCBP1 in hyperproliferative diseases. No clinical-stage assets or active human trials are currently reported.
- Therapeutic areas
- OtherOncology
- Modalities
- Therapeutic antibodiesGene therapiesRegenerative medicine
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Ibex Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ibex Biosciences.